101 related articles for article (PubMed ID: 17264528)
1. Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.
Cicin I; Karagol H; Uzunoglu S; Uygun K
Onkologie; 2007 Feb; 30(1-2):65. PubMed ID: 17264528
[No Abstract] [Full Text] [Related]
2. Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Paran H; Edelstein E; Klein B; Gutman M
Isr Med Assoc J; 2007 Jun; 9(6):488-9. PubMed ID: 17642404
[No Abstract] [Full Text] [Related]
3. [A case of liver metastases from rectal cancer showed a complete response by FOLFIRI and bevacizumab chemotherapy].
Kuwada A; Nakamitsu A; Imamura Y; Kouyama M; Uekami S; Touge K; Taogoshi H; Fukuda Y; Daimaru H
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2937-40. PubMed ID: 21160275
[TBL] [Abstract][Full Text] [Related]
4. [A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
Nishida K; Matsuyama T; Masuda D; Hosokawa T; Tokita H; Kakimoto M; Goto H; Yoshimura T; Koshiishi H; Okamura T
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2517-9. PubMed ID: 21224625
[TBL] [Abstract][Full Text] [Related]
5. Perforating dermatosis in a patient receiving bevacizumab.
Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
[No Abstract] [Full Text] [Related]
6. [Management for adverse events associated with FOLFIRI plus cetuximab or panitumumab].
Masuishi T; Muro K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():587-91. PubMed ID: 25831828
[No Abstract] [Full Text] [Related]
7. [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
Hoshino H; Ishii Y; Hasegawa H; Endo T; Ochiai H; Hoshino Y; Matsunaga A; Shigeta K; Seo Y; Hoshino G; Kitagawa Y
Gan To Kagaku Ryoho; 2012 Jun; 39(6):983-6. PubMed ID: 22705698
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of bevacizumab for advanced colorectal cancer].
Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
[TBL] [Abstract][Full Text] [Related]
9. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
10. Bevacizumab-associated reversible hypotension.
Iqbal K; Chu Q; Mei Q; Chen Y
Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):800-1. PubMed ID: 17825542
[No Abstract] [Full Text] [Related]
11. [Improving longevity in advanced intestinal cancer].
Schmoll HJ
Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
[No Abstract] [Full Text] [Related]
12. Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Maleux G; Vaninbroukx J; Heye S; van Cutsem E; Oyen R
Acta Oncol; 2010 Aug; 49(6):864-6. PubMed ID: 20230212
[No Abstract] [Full Text] [Related]
13. [Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer].
Murata K; Mikami K; Yamada M; Ide Y; Owada Y; Nishigaki T; Nagase H; Mukai R; Momozane T; Murakami M; Okada K; Yanagisawa T; Ebisui C; Yokouchi H; Kinuta M
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2605-7. PubMed ID: 21224653
[TBL] [Abstract][Full Text] [Related]
14. Update: NCCN colon and rectal cancer clinical practice guidelines.
Kiel K; Engstrom PF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-14-8. PubMed ID: 23570093
[No Abstract] [Full Text] [Related]
15. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
[No Abstract] [Full Text] [Related]
16. [Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].
Tagami Y; Ogata S; Katakawa M; Bando Y
Gan To Kagaku Ryoho; 2012 Feb; 39(2):317-9. PubMed ID: 22333652
[TBL] [Abstract][Full Text] [Related]
17. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Donadon M; Vauthey JN; Loyer EM; Charnsangavej C; Abdalla EK
World J Gastroenterol; 2006 Oct; 12(40):6556-8. PubMed ID: 17072991
[TBL] [Abstract][Full Text] [Related]
18. New treatments for colorectal cancer.
FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
[No Abstract] [Full Text] [Related]
19. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
[TBL] [Abstract][Full Text] [Related]
20. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
